FindTrial
Sign In

MY008211A tablets

DRUG11 trials

Sponsors

Wuhan Createrna Science and Technology Co., Ltd

Conditions

Hepatic Insufficiency (MeSH ID: D048550)IgA Nephropathy (IgAN)Paroxysmal Nocturnal Haemoglobinuria (PNH)Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria (PNH)

Phase 1

A Study of Single-dose MY008211A in Healthy Adults
CompletedNCT05642585
Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Hemoglobinuria
Start: 2022-05-27End: 2023-06-04Updated: 2023-09-08
A Study of Multiple Ascending Doses MY008211A in Healthy Adults
CompletedNCT05828472
Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Hemoglobinuria
Start: 2023-01-10End: 2023-06-30Updated: 2023-09-08
Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects
CompletedNCT05828485
Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Hemoglobinuria
Start: 2022-09-26End: 2022-10-23Updated: 2023-04-25
To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects
Not yet recruitingNCT06543459
Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Hemoglobinuria
Start: 2024-08-10End: 2024-12-13Target: 16Updated: 2024-08-09
A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function
CompletedNCT07625618
Wuhan Createrna Science and Technology Co., LtdHepatic Insufficiency (MeSH ID: D048550)
Start: 2024-09-20End: 2024-12-28Updated: 2026-06-04

Phase 2

A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
CompletedNCT06050226
Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Hemoglobinuria
Start: 2023-07-06End: 2024-11-28Updated: 2025-07-30
Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Not yet recruitingNCT06134414
Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Hemoglobinuria (PNH)
Start: 2025-12-31End: 2027-12-31Target: 40Updated: 2025-07-29
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Not yet recruitingNCT06687174
Wuhan Createrna Science and Technology Co., LtdIgA Nephropathy (IgAN)
Start: 2024-12-31End: 2028-01-31Target: 72Updated: 2024-11-18
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
RecruitingNCT06933914
Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Hemoglobinuria (PNH)
Start: 2024-11-30End: 2026-12-30Target: 120Updated: 2025-04-18

Phase 3

Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
RecruitingNCT06932471
Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Hemoglobinuria
Start: 2024-08-30End: 2025-12-30Target: 20Updated: 2025-05-09
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
RecruitingNCT06932744
Wuhan Createrna Science and Technology Co., LtdParoxysmal Nocturnal Haemoglobinuria (PNH)
Start: 2024-08-30End: 2025-12-30Target: 66Updated: 2025-05-09